Depomed to Announce Second Quarter 2007 Financial Results on Tuesday, August 7

Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second quarter results for 2007 after the market closes on Tuesday, August 7 , 2007. The company will webcast a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results and to provide an update and future outlook on company events.

Interested parties can access the live and archived broadcast of the call at www.depomedinc.com.

About Depomed

Depomed, Inc., is a specialty pharmaceutical company with two approved products on the market and multiple product candidates in its pipeline. The company utilizes its proven, proprietary AcuForm™ drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Glumetza™ (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in the United States by King Pharmaceuticals and in Canada by Biovail Corporation. ProQuin® XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is marketed by Watson Pharmaceuticals. Product candidate Gabapentin GR™ is currently in clinical development for the treatment of two pain indications, postherpetic neuralgia and diabetic peripheral neuropathy. A Phase 2 clinical trial of Gabapentin GR in menopausal hot flashes is ongoing. Additional information about Depomed may be found on its web site, www.depomedinc.com.